Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H11NO4S2 |
Molecular Weight | 249.307 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CSCC(=O)NC1CCSC1=O
InChI
InChIKey=QGFORSXNKQLDNO-UHFFFAOYSA-N
InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)
Molecular Formula | C8H11NO4S2 |
Molecular Weight | 249.307 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.erdosteine.net/Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf
Sources: http://www.erdosteine.net/
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf
Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070254 |
|||
Target ID: P08246 Gene ID: 1991.0 Gene Symbol: ELANE Target Organism: Homo sapiens (Human) |
|||
Target ID: GO:1903409 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ERDOTIN Approved UseMucolytic agent in acute and chronic respiratory diseases. |
|||
Primary | ERDOTIN Approved UseMucolytic agent in acute and chronic respiratory diseases. |
PubMed
Title | Date | PubMed |
---|---|---|
Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. | 2001 May-Jun |
|
The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils. | 2002 |
|
The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. | 2002 |
|
Effects on the reactive oxygen species of erdosteine and its metabolite in vitro. | 2002 |
|
The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. | 2004 |
|
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. | 2004 Dec 6 |
|
Inhibitory effects of metabolite I of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils. | 2004 Jul |
|
Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. | 2004 Jun 28 |
|
Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. | 2004 Sep 30 |
|
Erdosteine ameliorates PTZ-induced oxidative stress in mice seizure model. | 2005 May 30 |
|
Effect of metabolite I of erdosteine on the release of human neutrophil elastase. | 2006 |
|
The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells. | 2006 Feb 15 |
|
Erdosteine against acetaminophen induced renal toxicity. | 2006 Jul |
|
Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury. | 2006 Jul-Aug |
|
Future therapeutic treatment of COPD: struggle between oxidants and cytokines. | 2007 |
|
Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. | 2007 Dec |
|
Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. | 2007 Jan |
|
Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction. | 2007 Mar |
|
The effects of erdosteine, N-acetylcysteine and vitamin E on nicotine-induced apoptosis of cardiac cells. | 2007 May-Jun |
|
Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. | 2007 Sep |
|
The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats. | 2007 Sep 24 |
|
The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. | 2008 |
|
Antioxidant effect of sulphurous thermal water on human neutrophil bursts: chemiluminescence evaluation. | 2008 |
|
The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of hippocampal neural cells. | 2008 Aug 1 |
|
Antioxidant therapeutic advances in COPD. | 2008 Dec |
|
Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. | 2009 Feb-Apr |
|
Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. | 2010 Apr |
|
Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. | 2010 Aug |
|
Effects of sulphurous water on human neutrophil elastase release. | 2010 Dec |
|
Association between lung function and exacerbation frequency in patients with COPD. | 2010 Dec 9 |
|
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. | 2010 Jan 6 |
|
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. | 2010 Jul-Sep |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:22:17 UTC 2022
by
admin
on
Fri Dec 16 19:22:17 UTC 2022
|
Record UNII |
76J0853EKA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
417413
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
||
|
WHO-ATC |
R05CB15
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
||
|
WHO-VATC |
QR05CB15
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
||
|
NCI_THESAURUS |
C74536
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/12/1084
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C61750
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
C048498
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
SUB06595MIG
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
CHEMBL1697744
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
24305
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | RxNorm | ||
|
76J0853EKA
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
1041
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
DTXSID8048735
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
65632
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
M4974
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | Merck Index | ||
|
84611-23-4
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
ERDOSTEINE
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
DB05057
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
76J0853EKA
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY | |||
|
6032
Created by
admin on Fri Dec 16 19:22:17 UTC 2022 , Edited by admin on Fri Dec 16 19:22:17 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |